FORMULATION ARTICLES
-
![vaccine, vaccination, virus dna doubts questions-GettyImages-1308261360]( "The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics")
The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of TherapeuticsLong non-coding RNAs and splicing networks are emerging as master regulators of cellular identity, opening new therapeutic opportunities beyond proteins.
-
![Ribosome as part of an biological cell constructing mRNA molecule-GettyImages-1352440312]( "RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease Biology")
RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease BiologyRNA-binding proteins orchestrate splicing, stability, localization, and translation, emerging as powerful regulators and therapeutic targets in disease.
-
![Emergency medicine-GettyImages-2055655561]( "Targeting The Uncharted Heart: Why The Next Era Of siRNA Belongs In Cardiology")
Targeting The Uncharted Heart: Why The Next Era Of siRNA Belongs In CardiologyDuring our conversation, Gallagher walked me through what’s keeping her up at night as she leads the company and its first siRNA candidate toward an IND, elaborating on the role RNA can play in cardiomyopathies and identifying the unique challenges of developing RNA medicines today.
-
![molecular scissors, manipulation of molecular biology, RNA molecule-GettyImages-2213997299]( "Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics")
Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi TherapeuticsAs siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.
-
![GettyImages-1487902757]( "Following The Data To The Heart: Atrium's Quest For Next-Gen Targeted RNA Delivery")
Following The Data To The Heart: Atrium's Quest For Next-Gen Targeted RNA DeliveryIn this two-part series, Gallagher shares more about her goals for Atrium following its spin-out from Novartis, articulating what it looks like and means to “pave a path” to greater patient access in rare cardiomyopathies. Here in part one, we start with a look into the formation of Atrium, sharing the “why” behind the company’s formation and what’s next for the company’s targeted delivery platform.
-
![RNA, siRNA, mRNA, CRISPR-GettyImages-1409578455]( "Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2)")
Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2)Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.
FORMULATION VIDEOS
The quest for the “extra-hepatic GalNAc” is on. In this Advancing RNA Live clip, NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris walk through some of the most popular targeting ligand choices being explored in the RNA delivery space today, sharing which they believe will be the most game-changing.
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?
Overcome LNP upscaling challenges by leveraging fluid mechanical principles. Learn how Impingement Jets Mixing achieves reproducible turbulence and consistent LNP quality across all production scales.
Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1298788278 drug manufacturing]( "Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing")
Learn about a continuous manufacturing platform designed to help overcome challenges in domestic pharmaceutical production, including scale-up barriers and production variability.
-
![mRNA GettyImages-1428646288]( "Establishing Analytical Methods For mRNA-Based Therapies")
Here, we provide a detailed description of assays for sequence identification and LNP composition in mRNA-LNP products that support the development of safe and effective mRNA therapies.
-
![mRNA GettyImages-1428646288]( "Early Spectroscopic Insights Into RNA Modifications In LNP Formulations With MMS")
Understand how Microfluidic Modulation Spectroscopy (MMS) provides early insights into RNA degradation within LNP formulations, offering a label-free approach to monitoring chemical integrity.
-
![GettyImages-1409578453-mRNA-LNP-lipid-nanoparticle-RNA therapy]( "Optimized And Scalable LNP Composition For RNA Vaccine Delivery")
Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications.
-
![Worker Holding Vaccine Vial GettyImages-1403976499]( "LNP Formulation For mRNA Delivery")
Microfluidic mixing is one of the most effective means to formulate LNPs for its scalability and reproducibility. Explore LNP formulation, polishing, sterile filtration of mRNA-LNPs, and more.
-
![Science techonlogy-research-development-discovery-GettyImages-1209662272]( "Turbulent Mixing: Scaling Up Nanoparticle Manufacturing For The Future")
Choosing between turbulent and microfluidic mixing methods in your lipid nanoparticle (LNP) production can have a significant impact when scaling up production.
-
Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.
